Trials / Completed
CompletedNCT00385099
Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome
A Phase IIa Pharmacodynamic Study of Antagonism of Irritable Bowel Syndrome (IBS) Symptoms by GW876008, a Corticotrophin Releasing Factor 1 Receptor Antagonist (CRF1-RA)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if GW876008 in Irritable Bowel Syndrome patients will reverse stress-induced hypersensitivity, by looking at thresholds for perception and pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW876008 |
Timeline
- Start date
- 2006-12-08
- Primary completion
- 2007-10-15
- Completion
- 2007-10-15
- First posted
- 2006-10-06
- Last updated
- 2017-08-08
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00385099. Inclusion in this directory is not an endorsement.